Sarepta Therapeutics Inc. (SRPT) Stock Rating Reaffirmed by JMP Securities
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reissued by equities research analysts at JMP Securities in a report issued on Thursday.
Several other research firms have also commented on SRPT. Jefferies Group set a $58.00 price target on shares of Sarepta Therapeutics and gave the company a “hold” rating in a report on Sunday, October 2nd. Wedbush restated an “outperform” rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, September 20th. Royal Bank Of Canada dropped their price objective on shares of Sarepta Therapeutics to $106.00 and set an “outperform” rating on the stock in a research note on Friday, October 28th. Piper Jaffray Cos. set a $68.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 4th. Finally, Cowen and Company restated an “outperform” rating and issued a $64.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, October 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $66.28.
Sarepta Therapeutics (NASDAQ:SRPT) traded up 2.5174% during trading on Thursday, reaching $38.5363. 617,548 shares of the company were exchanged. The stock has a 50 day moving average price of $48.09 and a 200 day moving average price of $30.50. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The firm’s market capitalization is $2103.70 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, October 27th. The company reported ($0.95) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.32) by $0.37. During the same quarter last year, the firm earned ($1.25) earnings per share. On average, analysts expect that Sarepta Therapeutics will post ($4.31) EPS for the current fiscal year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP David T. Howton sold 7,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $420,000.00. Following the transaction, the senior vice president now directly owns 28,453 shares in the company, valued at approximately $1,707,180. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas boosted its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Cornerstone Capital Management Holdings LLC. acquired a new position in Sarepta Therapeutics during the third quarter valued at $140,000. Advisor Group Inc. acquired a new position in Sarepta Therapeutics during the second quarter valued at $154,000. Winslow Evans & Crocker Inc. acquired a new position in Sarepta Therapeutics during the third quarter valued at $209,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in Sarepta Therapeutics during the second quarter valued at $211,000. 65.91% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.